Similar articles

• High-dose-rate versus low-dose-rate monotherapy in the treatment of localized prostate cancer. The case for high-dose-rate monotherapy: An up and coming treatment option for low-risk prostate cancer.

  Sylvester JE. Sylvester JE. Brachytherapy. 2006 Jan-Mar;5(1):1-4; discussion 7. doi: 10.1016/j.brachy.2006.01.001. Brachytherapy. 2006. PMID: 16563988 Review. No abstract available.
• [Brachytherapy for prostate cancer: high dose rate or low-dose rate?].

  Cosset JM, Haie-Meder C. Cosset JM, et al. Cancer Radiother. 2005 Dec;9(8):610-9. doi: 10.1016/j.canrad.2005.09.019. Epub 2005 Oct 13. Cancer Radiother. 2005. PMID: 16226473 Review. French.
• Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.

  Momma T, Saito S, Toya K, Yorozu A, Dokiya T, Murai M. Momma T, et al. Int J Urol. 2006 Mar;13(3):218-23. doi: 10.1111/j.1442-2042.2006.01266.x. Int J Urol. 2006. PMID: 16643612
• Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.

  Dattoli M, Wallner K, True L, Cash J, Sorace R. Dattoli M, et al. Urology. 2007 Feb;69(2):334-7. doi: 10.1016/j.urology.2006.09.045. Urology. 2007. PMID: 17320673
• Radiation dose predicts for biochemical control in intermediate-risk prostate cancer patients treated with low-dose-rate brachytherapy.

  Ho AY, Burri RJ, Cesaretti JA, Stone NN, Stock RG. Ho AY, et al. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):16-22. doi: 10.1016/j.ijrobp.2008.10.071. Epub 2009 Mar 14. Int J Radiat Oncol Biol Phys. 2009. PMID: 19289266